GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Abbott Laboratories (NYSE:ABT) » Definitions » PB Ratio

Abbott Laboratories (Abbott Laboratories) PB Ratio

: 4.73 (As of Today)
View and export this data going back to 1949. Start your Free Trial

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-18), Abbott Laboratories's share price is $105.27. Abbott Laboratories's Book Value per Share for the quarter that ended in Dec. 2023 was $22.26. Hence, Abbott Laboratories's PB Ratio of today is 4.73.

The historical rank and industry rank for Abbott Laboratories's PB Ratio or its related term are showing as below:

ABT' s PB Ratio Range Over the Past 10 Years
Min: 2.19   Med: 3.93   Max: 7.15
Current: 4.73

During the past 13 years, Abbott Laboratories's highest PB Ratio was 7.15. The lowest was 2.19. And the median was 3.93.

ABT's PB Ratio is ranked worse than
77.85% of 799 companies
in the Medical Devices & Instruments industry
Industry Median: 2.18 vs ABT: 4.73

During the past 12 months, Abbott Laboratories's average Book Value Per Share Growth Rate was 5.40% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 6.30% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 5.50% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 4.40% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Abbott Laboratories was 19.20% per year. The lowest was -5.30% per year. And the median was 10.20% per year.

Back to Basics: PB Ratio


Abbott Laboratories PB Ratio Historical Data

The historical data trend for Abbott Laboratories's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbott Laboratories Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.92 5.92 6.93 5.20 4.94

Abbott Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.20 4.76 5.09 4.49 4.94

Competitive Comparison

For the Medical Devices subindustry, Abbott Laboratories's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abbott Laboratories PB Ratio Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Abbott Laboratories's PB Ratio distribution charts can be found below:

* The bar in red indicates where Abbott Laboratories's PB Ratio falls into.



Abbott Laboratories PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Abbott Laboratories's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=105.27/22.261
=4.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Abbott Laboratories  (NYSE:ABT) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Abbott Laboratories PB Ratio Related Terms

Thank you for viewing the detailed overview of Abbott Laboratories's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Abbott Laboratories (Abbott Laboratories) Business Description

Address
100 Abbott Park Road, Abbott Park, IL, USA, 60064-6400
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Executives
Andrea F Wainer officer: Executive Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Daniel J Starks director ONE ST JUDE MEDICAL DRIVE, ST PAUL MN 55117
Mccoy John A. Jr. officer: VICE PRESIDENT C/O ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Michael F Roman director 3M COMPANY OFFICE OF GENERAL COUNSEL, 3M CENTER, ST. PAUL MN 55144-1000
Patricia Paola Gonzalez director 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Louis H. Morrone officer: EXECUTIVE VICE PRESIDENT 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Philip P Boudreau officer: Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Michael O'grady director 50 S LASALLE STREET, CHICAGO IL 60603
Gregory A Ahlberg officer: Senior Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Randel William Woodgrift officer: Senior Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
John F Ginascol officer: Executive Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Salvadori Daniel Gesua Sive officer: Senior Vice President 100 ABBOTT PARK ROAD, AP6A-2, D-032L, ABBOTT PARK IL 60064-6092
Mary K Moreland officer: Executive Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Lisa D Earnhardt officer: Executive Vice President 1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025
Robert E Funck officer: Vice President, Controller 100 ABBOTT PARK ROAD, D-378, AP6D-2, ABBOTT PARK IL 60064-6092

Abbott Laboratories (Abbott Laboratories) Headlines

From GuruFocus

Q1 2022 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2021 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q1 2021 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2023 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2022 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2019 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024